Biopharmx Corp (BPMX) Stock Rating Reaffirmed by Maxim Group
Biopharmx Corp (NASDAQ:BPMX)‘s stock had its “buy” rating reissued by investment analysts at Maxim Group in a report released on Wednesday. They currently have a $1.50 target price on the stock, down from their previous target price of $3.00. Maxim Group’s price target would indicate a potential upside of 400.00% from the stock’s current price.
A number of other research firms also recently issued reports on BPMX. HC Wainwright set a $3.00 price target on shares of Biopharmx Corp and gave the company a “buy” rating in a research report on Thursday, June 15th. Roth Capital set a $3.00 price target on shares of Biopharmx Corp and gave the company a “buy” rating in a research report on Saturday, June 3rd.
Shares of Biopharmx Corp (BPMX) traded down 11.76% during trading on Wednesday, hitting $0.30. The company’s stock had a trading volume of 1,388,964 shares. The stock’s market cap is $22.24 million. Biopharmx Corp has a one year low of $0.19 and a one year high of $0.90. The company has a 50-day moving average price of $0.31 and a 200-day moving average price of $0.48.
Biopharmx Corp (NASDAQ:BPMX) last posted its quarterly earnings results on Tuesday, June 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.07). Biopharmx Corp had a negative net margin of 28,405.26% and a negative return on equity of 1,847.04%. The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.03 million. Equities analysts predict that Biopharmx Corp will post ($0.31) EPS for the current fiscal year.
In related news, major shareholder Franklin Resources Inc purchased 250,000 shares of Biopharmx Corp stock in a transaction dated Tuesday, August 1st. The stock was bought at an average cost of $0.34 per share, for a total transaction of $85,000.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Several institutional investors have recently modified their holdings of BPMX. Vivo Capital LLC raised its position in shares of Biopharmx Corp by 10.0% during the 2nd quarter. Vivo Capital LLC now owns 14,096,338 shares of the company’s stock worth $6,752,000 after purchasing an additional 1,282,052 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Biopharmx Corp by 324.6% during the 2nd quarter. Vanguard Group Inc. now owns 1,933,747 shares of the company’s stock worth $927,000 after purchasing an additional 1,478,338 shares during the last quarter. Finally, Virtu KCG Holdings LLC raised its position in shares of Biopharmx Corp by 366.2% during the 2nd quarter. Virtu KCG Holdings LLC now owns 503,418 shares of the company’s stock worth $241,000 after purchasing an additional 395,424 shares during the last quarter.
About Biopharmx Corp
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Stock Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related stocks with our FREE daily email newsletter.